851645-51-7

Basic information

• Product Name: 4-{{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl]hept-1-yl}-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine naphthalene-1,5-disulfonic acid salt
• Synonyms: 4-{{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl]hept-1-yl}-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine naphthalene-1,5-disulfonic acid salt
• CAS NO: 851645-51-7
• Molecular Weight: 928.227
• Mol File: 851645-51-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-{{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl]hept-1-yl}-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine naphthalene-1,5-disulfonic acid salt(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl]hept-1-yl}-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine naphthalene-1,5-disulfonic acid salt(851645-51-7)
• EPA Substance Registry System: 4-{{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl]hept-1-yl}-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine naphthalene-1,5-disulfonic acid salt(851645-51-7)

Safety Data

• Hazardous Substances Data: 851645-51-7(Hazardous Substances Data)

Upstream product

• 690999-15-6 TD-6301 
• 81-04-9 naphthalene-1,5-disulfonate 

Relevant articles and documents

Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds

Processes and intermediates for preparing substituted 4-amino-1-(pyridylmethyl)-piperidine and related compounds in high yield and high purity are described. The substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds prepared by the describ

SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE AND RELATED COMPOUNDS

This invention provides 4-amino-1-(pyridylmethyl)piperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.